All In Biotech

Drug Trial Radar · NCT04368559

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study)

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 602 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

602

Actual

Start

May 11, 2020

Primary completion

Jan 29, 2026

Study completion Jan 29, 2026

Sponsor

Lead sponsor
Mundipharma Research LimitedIndustry
Sponsor type
Industry
First posted
Apr 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the prevention of invasive fungal diseases when compared to the standard antimicrobial regimen.

Conditions

  • Candidemia
  • Mycoses
  • Fungal Infection
  • Fungemia
  • Invasive Candidiasis
  • Pneumocystis
  • Mold Infection
  • Invasive Fungal Disease
  • Prophylaxis of Invasive Fungal Infections
  • Aspergillus

Interventions

  • Rezafungin for InjectionDrug

    Intravenous antifungal therapy

  • PosaconazoleDrug

    Oral antifungal therapy

  • FluconazoleDrug

    Oral antifungal therapy

  • Trimethoprim-sulfamethoxazole (TMP/SMX)Drug

    Oral antibacterial therapy

  • Intravenous PlaceboDrug

    Normal saline

  • Oral PlaceboDrug

    Microcrystalline cellulose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Noninferior Fungal-Free Survival (US FDA)Time frame: Day 90 (±7 days)
  2. Noninferior Fungal-Free Survival (US FDA)Time frame: Day 90 (±7 days)
  3. Superior Fungal-Free Survival (EMA)Time frame: Day 90 (±7 days)
  4. Superior Fungal-Free Survival (EMA)Time frame: Day 90 (±7 days)

Locations

53 sites in 9 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • UCLA Center for Health Sciences

    Los Angeles, California

  • Stanford University School of Medicine

    Stanford, California

  • Augusta University Medical Center

    Augusta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • University of Maryland Medical Center

    Baltimore, Maryland

  • John Hopkins

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Minnesota Physicians

    Minneapolis, Minnesota

  • Mayo Clinic

    Rochester, Minnesota

  • Mary Hitchcock Memorial Hospital Dartmouth-Hitchcock

    Lebanon, New Hampshire

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Stony Brook University Hospital

    Stony Brook, New York

  • The University of Oklahoma College of Medicine

    Oklahoma City, Oklahoma

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • VCU Medical Center Main Hospital

    Richmond, Virginia

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • University Hospitals Leuven, Campus Gasthuisberg - UZ Leuven

    Leuven, Belgium

  • AZ Sint-Jan

    Bruges, West Vlaanderen, Belgium

  • Hamilton Health Sciences' Juravinski Hospital

    Hamilton, Canada

  • McGill University Health Center

    Montreal, Canada

  • Jean Minjoz Hospital

    Besançon, France

  • Henri Mondor Hospital

    Créteil, France

  • Grenoble Alpes University Hospital Center

    Grenoble, France

  • University Hospital of Limoges

    Limoges, France

  • University Hospital of Nantes

    Nantes, France

  • Hospital Saint Antoine Ap-Hp

    Paris, France

  • University Hospital of Bordeaux

    Pessac, France

  • Lyon-Sud Hospital Center

    Pierre-Bénite, France

  • University Hospital of Cologne

    Cologne, Germany

  • University Hospital Carl Gustav Carus Dresden

    Dresden, Germany

  • Johannes Gutenberg University Medical Center

    Mainz, Germany

  • University Hospital Münster

    Münster, Germany

  • University Hospital Wurzburg UKW

    Würzburg, Germany

  • San Martino Polyclinic Hospital

    Genova, Italy

  • IEO Istituto Europeo di Oncologia

    Milan, Italy

  • Agostino Gemelli University Policlinic

    Rome, Italy

  • Humanitas Cancer Center

    Rozzano, Italy

  • University Hospital Vall d'Hebron

    Barcelona, Spain

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.